• Hamlet Biopharma in fiscal 2025/2026 expanded a US clinical study with the University of Iowa in high-risk, resistant NMIBC.
• Results have not been presented yet; the study aims to test Alpha1H in carcinoma in situ, a severe, treatment-resistant form.
• Earlier Phase II results in NMIBC were already presented, supporting efficacy and safety without meaningful side effects.
• European regulators cleared a Phase III Alpha1H bladder-cancer study on June 29, 2026, setting up a pivotal program.
• Phase III-quality Alpha1H manufacturing was released on June 25, 2026, enabling distribution to clinical trial sites.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hamlet Biopharma AB published the original content used to generate this news brief via Cision (Ref. ID: 202608280300BITN____UKPR__EN_20260827-BIT-3009-0) on August 28, 2026, and is solely responsible for the information contained therein.